secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001193125-25-059398
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports durable improvements in swallowing function with BB-301 in OPMD interim results
--------------------------------------------------------------------------------

- Three subjects treated with low-dose BB-301 showed significant, clinically meaningful improvements in swallowing function at 12 months (Subjects 1,2) and 3 months (Subject 3) post-treatment.
- Subject 1: 41% reduction in SSQ total symptom burden at 12 months; VFSS showed reductions in pharyngeal residue across all food and liquid consistencies.
- Subjects 2 and 3: near-complete resolution of pathologic sequential swallows; Subject 2 achieved clinically normal SSQ (68 units) at 12 months, Subject 3 at 3 months (70 units).
- No severe adverse events reported; five subjects safely treated; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525059398/0001193125-25-059398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525059398/d906340d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-059398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer